🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: ARV Background Regimen

Found 12 matching trials

A Randomised Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir (TPV) Plus 100 mg or 200 mg Ritonavir (RTV) p.o. BID in Comparison to 400 mg Lopinavir (LPV) Plus 100 mg RTV p.o. BID in Combination With Standard Background Regimen in ARV Therapy naïve Patients.

PHASE2

Evaluation of safety and efficacy of Tipranavir (TPV) boosted with Ritonavi...

Status

Terminated

Location

Boehringer Ingelheim Investigational Site

Start Date

2004-02

Trial ID

NCT00144105

Treatments Being Tested

TPV500mg/RTV200mgBID TPV500mg/RTV100mgBID LPV400mg/RTV100mgBID

A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed

PHASE2

The purpose of this study is to evaluate the steady state pharmacokinetics ...

Status

Completed

Location

ASST Spedali Civili di Brescia

Start Date

2019-07-18

Trial ID

NCT04012931

Treatments Being Tested

Rilpivirine ARV Background Regimen

A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy

PHASE2

This phase 2b study is designed to assess the long-term efficacy (24 weeks)...

Status

Terminated

Location

AIDS Healthcare Foundation Research Center

Start Date

2009-11

Trial ID

NCT01026727

Treatments Being Tested

MPC-4326 plus a 2-3 drug optimized background regimen (OBR)3-4 commercially available antiretroviral drugs

Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)

PHASE4

People infected with HIV often have cognitive dysfunction even if they are ...

Status

Completed

Location

UCLA CARE Center CRS

Start Date

2016-04-21

Trial ID

NCT02519777

Treatments Being Tested

Placebo for maraviroc (MVC)Placebo for dolutegravir (DTG)Dolutegravir (DTG)Maraviroc (MVC)

Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children

PHASE1

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are widely used as...

Status

Completed

Location

Pediatric Perinatal HIV Clinical Trials Unit CRS

Start Date

2013-03-14

Trial ID

NCT01504841

Treatments Being Tested

Etravirine (ETR)

A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients

PHASE4

This 2-arm study evaluated the efficacy and safety of Fuzeon with an integr...

Status

Terminated

Location

Multiple Locations

Start Date

2007-06

Trial ID

NCT00488059

Treatments Being Tested

enfuvirtide [Fuzeon]Optimized background ARV Integrase inhibitor enfuvirtide [Fuzeon]

Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients

PHASE2

This is an open-label, randomized, parallel group pharmacokinetics trial of...

Status

Completed

Location

Boehringer Ingelheim Investigational Site

Start Date

2003-02-18

Trial ID

NCT00056641

Treatments Being Tested

tipranavir ritonavir saquinavir amprenavir lopinavir

Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants

PHASE2

The primary objectives of this study are to evaluate the safety, tolerabili...

Status

Terminated

Location

University of Colorado Denver

Start Date

2013-08-26

Trial ID

NCT01923311

Treatments Being Tested

EVG Background regimen

INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.

PHASE2

This 2 arm study will assess the efficacy and safety of a new regimen of Fu...

Status

Completed

Location

Multiple Locations

Start Date

2008-01

Trial ID

NCT00615134

Treatments Being Tested

enfuvirtide [Fuzeon]Optimized background ARV therapy

UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection

PHASE3

The purpose of this phase III study is to evaluate the efficacy between tre...

Status

Unknown

Location

Multiple Locations

Start Date

2023-12-01

Trial ID

NCT04406727

Treatments Being Tested

UB-421 Antiretroviral (ARV)

Previous Next